Sanofi India planning to lower price of Rifapentine

31 Oct 2019 Evaluate

Sanofi India is planning to lower the price of Rifapentine, a critically important drug used to prevent tuberculosis (TB), as part of the agreement with Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria.

The volume-based agreement will discount the price of a three-month treatment course of Rifapentine by nearly 70 percent, from approximately $45 to $15 (ex works) in the public sectors of 100 low and middle-income countries burdened by TB and TB/HIV coinfection. Scale-up of affordable Rifapentine stands to benefit over a million people in India alone, where more people suffer from TB than anywhere else in the world. The Indian government has set ambitious targets to eliminate TB by 2025.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi India Share Price

8359.20 -177.30 (-2.08%)
07-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.15
Dr. Reddys Lab 6277.10
Cipla 1388.00
Zydus Lifesciences 980.65
Lupin 1610.55
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.